Clinical trial · Interventional
The Efficacy and Safety of Beta-blockers Drugs in Adults With Spinal Hemangioma
The Efficacy and Safety of Beta-blockers Drugs in Adults With Spinal Hemangioma: a Prospective Cohort Study
NCT05106179CI-TRIAL-00054827unknownPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Spinal hemangioma is one of the most common benign vertebral tumours. Being mostly asymptomatic, it is still associated with a pain syndrome especially if encroaches into the neural canal. This study is organised to evaluate the efficacy and safety of β-blockers drugs in adults with spinal hemangioma.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Beta Blocker Toxicity | — | UNRESOLVED | — |
| Spinal Hemangioma | — | UNRESOLVED | — |
| Spinal Tumor | Spinal Cord Neoplasm | PROBABILISTIC | 0.70 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Atenolol Pill | Drug | — | UNRESOLVED |
| Propranolol Pill | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Previously treated + Atenolol
- description
- The investigators suppose the outcome might be compromised if patient has been previously treated, that's why it is going to be compared to the main cohort. The results are going to be analysed separately
- interventionNames
- Drug: Atenolol Pill
- type
- ACTIVE_COMPARATOR
- label
- Previously treated + Propranolol
- description
- The investigators suppose the outcome might be compromised if patient has been previously treated, that's why it is going to be compared to the main cohort. The results are going to be analysed separately
- interventionNames
- Drug: Propranolol Pill
Primary outcomes (3)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: * vertebral hemangioma Exclusion Criteria: * symptomatic bradycardia * AV block * decompensated heart failure * asthma
References
Publications (0)
Data not yet available
No reference posted for this study.